{"title":"【回复关于“在意大利市场引入曲美替尼+达非尼联合治疗晚期黑色素瘤的临床和经济评价”的致编辑的信】","authors":"L. Pradelli, P. Ascierto","doi":"10.7175/FE.V18I1.1329","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":41585,"journal":{"name":"Farmeconomia-Health Economics and Therapeutic Pathways","volume":"84 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2017-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Reply to Letter to the Editor in reference to \\\" Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]\",\"authors\":\"L. Pradelli, P. Ascierto\",\"doi\":\"10.7175/FE.V18I1.1329\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":41585,\"journal\":{\"name\":\"Farmeconomia-Health Economics and Therapeutic Pathways\",\"volume\":\"84 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2017-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmeconomia-Health Economics and Therapeutic Pathways\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7175/FE.V18I1.1329\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmeconomia-Health Economics and Therapeutic Pathways","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7175/FE.V18I1.1329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]